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Introduction 
Two types of approaches may be used to evaluate the toxicity of environ-
mental agents: 
• Observational population studies may be used to investigate humans or 
animals in contact with the agent of interest, either prospectively or 
retrospectively.   
• Experimental studies may be performed under controlled conditions on 
animals, living tissues or cells. These results may be extrapolated to 
human and animal populations. 
 
Observational epidemiological studies of human and animal populations 
have the advantage of investigating the effects of environmentally relevant 
exposures to naturally–occurring mixtures of toxins.  Health effects may 
be identified in the target species of concern.  These studies are difficult to 
implement however, as monitoring of cyanobacteria toxin occurrence in 
ambient water is essential to document exposure status, and specific asso-
ciations between exposure and effect are difficult to establish in free–
living populations. 
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Health studies of standard test species in controlled environments ad-
dress some of the difficulties described above, but they often involve the 
use of species other than those of primary interest.  Laboratory studies may 
not closely approximate the toxin, dose or duration of exposure relevant to 
environmental conditions.  The effects of mixtures of natural materials and 
toxins may be difficult to reproduce during repeated experiments.  The ad-
vantages and disadvantages of these two strategies reveal that each may 
complement and enhance the other.  Neither approach is complete in itself. 
Both are essential to the understanding of the potential effects of cyano-
bacterial toxins on human and animal populations.   
The use of laboratory animals in toxicology is based on the premise that 
the data obtained during controlled exposures may be extrapolated with 
some degree of confidence to other species including our own.  Cyanobac-
terial toxins are a heterogeneous group of compounds with unrelated struc-
tures, toxic endpoints, and mechanisms of action.  Cyanobacterial toxins 
include hepatotoxins, renal toxins, immunotoxins, neurotoxins, skin irri-
tants and sensitizers, although mechanisms of pathogenesis are not fully 
understood.  Future cyanobacterial toxicity studies must consider the fol-
lowing components:  
1. Selection of test species.  The science of toxicology is replete with 
examples of highly significant inter–species variability.  Differences 
in susceptibility to acute toxicity (e.g. TCDD), carcinogenicity (e.g. 
aflatoxin), and teratogenicity (e.g. thalidomide) are well documented.  
The response of different test species to a given dose of 
cyanobacterial toxin will depend onspecies–related metabolic/ 
toxicokinetic characteristics and differences in sensitivity to the agent 
studied (toxicodynamics).  The majority of studies have used the 
mouse because it is the smallest rodent test species and therefore 
requires the least amount of toxin.  Rodents are commonly used test 
animals but other animals must be studied in order to address the 
occurrence of specific toxicity endpoints across species. 
Determination of the “appropriate” test species will therefore depend 
on the information known about the site(s) of action and metabolism 
of the study agent.  Although these factors are critical to 
understanding the effects of cyanobacterial toxins, there are major 
gaps in our knowledge of these factors for most of the toxins.  Given 
these data gaps, the generally accepted testing strategy is to utilize 
multiple test species and to compare the results obtained in each 
species with those known to occur in the target species of concern. 
2. Duration of exposure.  Studies need to be conducted that approximate 
environmental exposures to cyanobacterial toxins.  This may involve 
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multiple study designs as free–living populations may be exposed to 
cyanobacterial toxins chronically at low doses, and/or may experience 
episodic short–term exposures to high doses.  These different 
exposure scenarios may, in turn, result in different spectrums of 
toxicity.  For example, the data from cylindrospermopsin studies 
(Hawkins et al. 1997) have shown that the acute LD50 is 2000 ug/kg, 
contrasted with the 5–day LD50 of only 200 ug/kg.  This suggests 
that the mortality seen in the two exposure groups of animals may be 
the result of different types of injury, one type being acute, and the 
other cumulative.  Adequate characterization of cyanobacterial–
induced toxicity should include a range of exposure scenarios. 
3. Route of exposure.  Oral, inhalation, and cutaneous exposures to 
cyanobacterial toxins may be the most likely routes of exposure 
among human and animal populations.  Two episodes of human 
microcystin exposure by the intravenous route have been documented 
among patients undergoing dialysis (Jochimsen et al. 1998, Soares et 
al. 2006).  In contrast, most animal toxicology studies have reported 
health effects associated with intraperitoneal (i.p.) exposure to 
cyanobacterial toxins.  Expense and lack of sufficient test material are 
the primary reasons for most cyanobacterial toxin studies having been 
performed using the i.p. exposure route.  The oral route of admin-
istration has been prohibitively expensive for extended studies since 
the toxins are far less toxic orally than by the i.p. route (generally by 
factors of 10 or more).  Future laboratory animal studies should in-
clude oral, inhalation, and cutaneous exposures to evaluate effects 
that may be associated with these environmentally relevant exposure 
routes.   
 4. Characterization of cyanobacterial toxins and effects of mixtures.  
Multiple cyanobacteria genera produce the same toxin, and some 
produce multiple toxins.  Many cyanobacterial toxins have yet to be 
identified and/or characterized.  The production of cyanobacterial 
toxins can be highly variable, and factors associated with toxin gene 
expression are poorly understood.  Cylindrospermopsis raciborskii, 
for example, produces widely varying amounts of cylindrospermopsin 
depending upon its geographical location and environmental 
conditions.  A recently described cyanobacterial toxin is β–N–
methylamino–L–alanine (BMAA).  This compound may be 
associated with adverse neurological effects in humans.  It is possible 
that BMAA occurs in multiple species of cyanobacteria including 
some that occur in fresh water (Cox et al. 2005).  Microcystins may 
vary temporally, spatially and chemically within a water body, and 
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Studies designed to assess the effects of purified cyanobacterial toxins 
such as microcystin–LR, anatoxin–a, and cylindrospermopsin, are needed 
to: characterize toxicokinetics and toxicodynamics, develop biomarkers of 
exposure and effect, and study specific health effects.  However, this ap-
proach is hindered by a lack of toxin standards, and the fact that the study 
of individual toxins does not approximate environmentally relevant expo-
sures.  The use of cellular extracts from cyanobacterial clonal cultures ad-
dresses these limitations.  Cultures can be characterized, batched and used 
for multiple studies among laboratories.  The use of these cultures would 
allow effects research to proceed in the absence of toxin standards, and 
may be more representative of the spectrum and mix of toxins to which 
human and animal populations are exposed.     
Cyanobacteria occurrence is generally increasing as a result of eutrophi-
cation and warming of surface waters.  When human and domestic animal 
populations congregate around surface water sources their waste, and nu-
trients such as nitrogen and phosphorous, enters the water.  Local popula-
tions may depend on surface waters to provide drinking water, irrigation, 
food fish, and recreation.  However, as population densities increase, the 
occurrence of blooms increases, thus heightening the risk of human and 
animal exposure to cyanobacteria toxins.  Given the potency, heterogene-
ity, and documented occurrence of cyanobacterial toxins in US surface wa-
ters, they will increasingly be recognized as a serious public and environ-
mental health concern.   
Charge 1 
What materials do we need to perform health effects research? 
Ideally, investigators need well characterized, pure cyanobacterial toxins 
to perform toxicity and carcinogenicity studies.  The results of studies us-
microcystin variants differ significantly in their potential to induce 
mammalian toxicity (Sivonen and Jones 1999).  Experimental 
evidence also indicates that any given bloom may produce more than 
one cyanobacterial toxin and the resultant toxicity may be the result 
of additive and/or synergistic effects among these agents.  Studies on 
cyanobacterial cellular extracts containing either anatoxin–a or 
cylindrospermopsin have shown that the resulting toxicity was not 
directly proportional to the amount of toxin in the test material itself 
(Stevens and Krieger 1991; Falconer et al. 1999).  In both reports, the 
authors hypothesized the existence of other, as yet unidentified toxins 
that were contributing to the observed adverse effects.   
2     E.D. Hilborn et al. 
Chapter 26: Human Health Effects Workgroup Report      583 
ing pure toxins are easier to interpret, and have fewer confounding vari-
ables.  However, extended toxicity studies require significant quantities of 
toxin to dose sufficient numbers of animals by relevant routes of exposure 
(dermal, oral, and inhalation).  These studies are necessary for risk assess-
ment and the development of guidance values.  
Currently the supply of pure toxin is limited.  Only two oral dosing tox-
icity studies using pure microcystin (Fawell et al. 1994) and cylindrosper-
mopsin (Humpage and Falconer 2003) have been implemented to date.  
However, the impact of these types of studies is significant.  The Fawell 
study was used by the World Health Organization (WHO) as the basis for 
a Guideline Value determination for microcystins.  The cylindrospermop-
sin study is currently under review by WHO.  Despite the importance of 
these types of studies, few are conducted because sufficient quantities of 
purified toxin are not currently available.  There are published chemical 
synthesis methods for microcystins, including production of the 3–amino–
9–methoxy–2,6,8–trimethyl–10–phenyl–4,6–decadienoic acid (ADDA) 
residue which has been successfully synthesized (Humphrey et al. 1996; 
Candy et al.1999).  However, no commercial production of pure cylin-
drospermopsin in bulk has been reported.  Although research groups have 
reported chemical methods to synthesize cylindrospermopsin (Xie et al. 
2000), this method is prohibitively expensive due to the 20 steps required 
for synthesis.   
Few toxicology studies using pure toxins have been conducted in spe-
cies other than mice.  Because of the limited supply of pure toxin, mice are 
preferred as an animal model because of their size.  However, they may 
not be the best model for every target species or system of interest.  Alter-
natively, studies with thoroughly characterized toxic extracts of cyanobac-
teria have yielded valuable data for domestic animals, including a study 
with growing pigs which was also used by WHO in the derivation of the 
human drinking water guideline (Falconer et al. 1994). 
Pure toxin isolated from live cultures of cyanobacteria is available pri-
vately and commercially in limited amounts allowing the conduct of 
mechanistic studies which require less material.  Some investigators have 
used C. raciborskii cultures (Hawkins et al. 1997; Chiswell et al. 1999; 
Shaw et al. 2000).  Cylindrospermopsin has been purified from C. racibor-
skii cultures using high performance liquid chromatography (HPLC) 
(Chiswell et al. 1999).  Other investigators have conducted studies with 
highly purified cylindrospermopsin isolated from a bloom of Umezakia 
natans collected from Lake Mikata, Fukui, Japan (Harada et al. 1994; 
Terao et al. 1994).  Likewise, studies with approximately 95% pure micro-
cystin–LR have been conducted with toxin produced from Microcystis 
aeruginosa, laboratory strain 7820, and purified by HPLC (Hooser et al. 
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1990).  Limited quantities of characterized microcystin variants LA, LR, 
RR, and YR, cylindrospermopsin and nodularin are available commer-
cially from Sigma–Aldrich (St. Louis, MO, US) and microcystin variants 
LF, LR, LW, and RR from EMD Biosciences (San Diego, CA, US).  Al-
though the production method is not disclosed, these materials are sus-
pected to have been isolated from live cultures.  Regardless of source, it is 
always important to verify the identity and purity of these toxins, as inves-
tigators have reported inconsistencies in research results among different 
lots of toxins. 
Freeze–dried natural bloom material is more widely available in larger 
quantities for research studies.  Dr. Ian Falconer and his colleagues have 
conducted long–term microcystin toxicity and cancer promotion studies in 
mice with extracts from dried natural bloom material that was from a batch 
collected at Lake Mokoan in Victoria, Australia and from Malpas Dam in 
New South Wales, Australia (Falconer and Humpage 1996).  Both sources 
of material have been characterized and used in previous research (Fal-
coner et al. 1988, 1994).  Ten peaks exhibiting the characteristic absorb-
ance spectrum of microcystins were detected using HPLC analysis.  How-
ever, none of these peaks corresponded to microcystins for which 
standards were available (microcystin–LR, –YR, and –RR).  Bloom mate-
rials offer the advantage of reflecting real–world exposure scenarios.   
However, these materials have to be carefully evaluated for use in studies 
that may be included in risk assessments.  Bloom materials may not be 
completely characterized and the toxicity of the mixture may be greater 
than that of the identified individual components indicating that: 1) the 
mixture may contain additional unidentified toxins; 2) that there may be a 
synergistic effect among bioactive components of the bloom material.  
Since the lack of availability of pure cyanobacterial toxins is currently 
limiting the ability to perform health effects research, this workgroup 
strongly recommends the development and maintenance of bulk clonal 
cyanobacteria cultures shared among laboratories to facilitate screening, 
bioassay development and long–term exposure studies.  Extensive chemi-
cal and bioassay characterization of the test materials is needed to ensure 
appropriate interpretation of study results.  Due to the hazardous nature of 
these materials, clarification and standardization of the import/export regu-
lations is needed to facilitate the use of shared cyanobacterial test materials 
among laboratories (Metcalf et al. 2006).   
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Charge 1:  What materials do we need to perform health effects 
research? 
Near-term Research Priorities 
• Develop and maintain bulk clonal cyanobacteria cultures that can be 
shared among laboratories to facilitate screening, bioassay development 
and long–term exposure studies.    
Long-term Research Priorities 
• Develop lower cost methods of chemical synthesis to produce sufficient 
quantities of standard cyanobacterial toxins. 
Charge 2 
What are the health effects associated with chronic and episodic 
exposures?  
 
Risk assessments of the effects of cyanobacterial toxins on human and 
animal health require information produced during studies of chronic and 
episodic exposures, and are insufficient if based solely on studies of acute 
exposures and lethal endpoints.  However, much of our knowledge of tox-
icity rests upon acute exposures: poisoning of animals in the natural envi-
ronment, and laboratory animal studies of lethal endpoints.  Considerable 
advances have been made, however, in our understanding of the sub-lethal 
effects of cyanobacterial toxins, and this must become the focus of re-
search in order to insure continued progress in the understanding of the 
risks associated with cyanobacterial toxin exposures.  
There are strong experimental studies that demonstrate the tumor pro-
motion activity of microcystins and nodularin, and well–designed genotox-
icity studies that show cylindrospermopsin to be a potential carcinogen 
(Falconer 2005).  To perform effective risk assessment it is essential to 
carry out carcinogenicity studies on both groups of cyanobacterial toxins.  
The present limitation to both National Toxicology Program (NTP) proto-
col studies is the lack of available purified toxin.  It is preferable to use 
highly characterized toxic extracts of cultures rather than to indefinitely 
defer these essential carcinogenicity trials, as humans may be currently ex-
posed to cylindrospermopsin via drinking and recreational water exposure. 
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The highest priority work is to implement carcinogenicity trials with 
cylindrospermopsin because of the structure of the toxin, preliminary evi-
dence of carcinogenicity, and the current strength of evidence of genotox-
icity in a human lymphoblastoid cell line (Humpage et al. 2000a).  An in 
vivo study conducted by Falconer and Humpage provided preliminary evi-
dence of the carcinogenicity of cylindrospermopsin in mice (Falconer and 
Humpage 2001).   
Neurodevelopmental studies are required for all groups of cyanobacte-
rial toxins.  Currently little is known about neurodevelopmental toxicity. 
Early work with chronic Microcystis extract exposure to male and female 
mice throughout pregnancy showed cytotoxicity in the hippocampus of 
neonatal offspring (Falconer et al. 1988).  These studies are especially 
relevant as there is the potential for neonates to be exposed via drinking 
water in formula during a period of their rapid neurologic development.  
Immunomodulation and immunosuppression after exposure to micro-
cystins has been documented (Shen et al. 2003; Shi et al. 2004; Chen et al. 
2005).  Adverse effects on human leukocytes in vitro have been reported at 
very low doses (Hernandez et al. 2000).  The potential immunotoxic ef-
fects of microcystin in human and animal populations are uncharacterized.  
To our knowledge, no studies of the potential immunotoxic effects of cyl-
indrospermopsin have been reported.  
There is no strong evidence to date for the teratogenicity of microcystin 
and anatoxin–a (Chernoff et al. 2002, Rogers et al. 2005, MacPhail et al. 
2005).  Teratogenicity studies of cylindrospermopsin are underway.  Mul-
tigenerational studies are needed for most toxins although the implementa-
tion of these will need to be deferred until sufficient toxin or characterized 
clonal bloom material is available. 
Charge 2:  What are the health effects associated with chronic 
and episodic exposures? 
Near-term Research Priorities 
• Conduct carcinogenicity studies with cylindrospermopsin.  
• Conduct neurodevelopmental studies for all groups of cyanobacterial 
toxins.   
• Conduct immunotoxicology studies for all groups of cyanobacterial 
toxins.   
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• Conduct studies of the effects of acute, episodic and chronic exposures 
at sublethal concentrations. 
• Implement toxicological studies using oral, inhalation, and cutaneous 
exposure routes.  
Long-term Research Priorities 
• Implement multigenerational studies for all groups of cyanobacterial 
toxins.  
Charge 3 
What are the health effects associated with environmental mix-
tures of toxins? 
 
In naturally occurring cyanobacterial blooms, a mixture of toxins is pre-
sent.  Most commonly, these are mixtures of microcystins when the bloom 
is Microcystis or Planktothrix or of cylindrospermopsins when the bloom 
is Cylindrospermopsis, Aphanizomenon, Raphidiopsis or Umezakia.  Ana-
toxin–a and anatoxin–a(s) are uncommonly found occurring with micro-
cystins or cylindrospermopsins in the environment, but when this mixture 
does occur, synergistic effects are possible.  Bloom toxicity therefore 
represents the combined toxicities of the constituent toxin variants present, 
and can best be expressed as toxicity equivalents (Falconer 2005).  
Under natural circumstances eutrophic water bodies form a sequence of 
toxic blooms that appear to be determined primarily by water temperature. 
An observed sequence in Australia is neurotoxic Anabaena, followed by 
hepatotoxic Microcystis, followed by cytotoxic Cylindrospermopsis in late 
summer (Bowling 1994).  Populations can then potentially be exposed to 
saxitoxins, followed by successive hepatotoxins with different mechanisms 
of action.   
Effective risk assessment of natural toxic bloom events requires a sys-
tematic assessment of mixtures of toxins for which there is currently no 
data.  We have little information about the health effects of exposure to 
concurrent or sequential mixtures.  Monitoring of cyanobacteria toxin oc-
currence in environmental samples is essential to detecting and under-
standing potentially associated health effects of exposure to mixtures of 
toxins.   
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Risk assessment of populations exposed to natural blooms needs to take 
into consideration a range of pathological effects generated by different 
cyanobacterial toxins, in sequence and in combination.  These may include 
measures of hepatic, immune system, and kidney impairment (Falconer 
2005).  In human populations, neurological impairment can be measured 
by the study of the neurodevelopment of young children and with a variety 
of standard tests among adults.  Cancer registries may be used to assess 
potential carcinogenetic effects of cyanobacterial toxins if large popula-
tions are found to be exposed. 
Charge 3: What are the health effects associated with 
environmental mixtures of toxins? 
 Near-term Research Priorities 
• Implement toxicology studies of animal models exposed to mixtures of 
cyanobacterial toxins to evaluate toxin synergism. 
• Implement epidemiologic studies of exposed populations to assess a 
variety of cyanobacterial toxin–associated health effects. 
• Perform risk assessments of populations exposed to natural blooms and 
multiple cyanobacterial toxins, in sequence and in combination. 
Charge 4 
What research is needed to better understand the public health 
effects of exposures to cyanobacteria? 
 
A well–designed study of the health effects associated with cyanobacteria 
exposure in human populations requires comprehensive exposure assess-
ment.  Currently, the United States does not routinely monitor drinking or 
recreational waters for the presence of cyanobacterial toxins despite the 
reported presence in these waters of potentially toxic blooms.  Therefore, 
the magnitude of the risk of cyanobacteria toxin exposure and associated 
effects to the US population is unknown.  Human exposures to cyanobac-
terial toxins may be broadly categorized for the purpose of public health 
investigation into acute or chronic (episodic) exposures.  Study methods 
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and approaches will vary depending upon the size of the population and 
the characteristics of exposure.  
Acute exposures to cyanobacteria and their toxins may occur via the 
oral, dermal, inhalational or intravenous exposure routes.  The most com-
mon exposures are believed to occur during recreational and occupational 
contact with cyanobacteria in lakes, rivers and marine waters (Osborne et 
al. 2001; Stewart et al. 2006).  Acute, chronic, and episodic exposures may 
arise from drinking water (Annadotter et al. 2001; Ressom et al. 1994; 
Kuiper–Goodman et al. 1999; Duy et al. 2000; Falconer 2005), dietary in-
take via consumption of cyanobacterial toxin–contaminated foods (Negri 
and Jones 1995; Nagai et al. 1996; Codd et al. 1999; Saker and Eaglesham 
1999; de Magalhães et al. 2001), and dietary supplements (Schaeffer et al. 
1999; Gilroy et al. 2000; Lawrence et al. 2001; Saker et al. 2005).  Acute 
human exposure has been documented via contamination of dialysate in 
hemodialysis clinics (Hindman et al. 1975; Carmichael et al. 2001; 
Azevedo et al. 2002; Soares et al. 2006).  Outcomes may range from no 
apparent effect to serious morbidity or death associated with toxicosis.  
Non life–threatening allergic and allergic–like reactions (rhinitis, asthma, 
eczema, conjunctivitis) have been reported but are poorly quantified, as are 
acute illnesses (e.g. flu–like reactions, skin rashes) in (presumably) non–
allergic individuals (Stewart et al. 2006).  
Reports of acute illness have been received from workers sampling po-
tentially toxic cyanobacteria blooms (Reich 2005).  These ranged from 
anaphylactic–like reactions, to dermatitis, gastroenteritis, and respiratory 
irritation.  However, published reports and descriptions of exposed and ill 
individuals (cases) and case series are needed as the literature is sparse 
(Turner et al. 1990).  This information is needed to develop more specific 
case definitions, to describe the spectrum of cyanobacteria–associated 
health effects, and to identify potential susceptibility factors.  
Chronic or episodic exposure to cyanobacterial toxins may occur when 
people are exposed occupationally or by their drinking water.  The princi-
pal concern is that some cyanobacterial toxins, such as the hepatotoxins, 
may have carcinogenic potential.  Some epidemiological investigations 
have suggested that hepatocellular carcinoma (HCC) and colorectal cancer 
rates were significantly higher in regions of China where consumption of 
untreated pond or ditch water was common when compared to rates in 
populations drinking deep well water (Ressom et al. 1994; Falconer 2005). 
However, the epidemiological evidence is contradictory; a recent retro-
spective study failed to identify a relationship between HCC and consump-
tion of ditch water (Yu et al. 2002).  China is a high–risk area for HCC, 
accounting for some 45% of worldwide mortality and HCC is associated 
with other risk factors such as chronic viral hepatitis and exposure to afla-
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toxins (Ming et al. 2002; Yu and Yuan 2004; Shi et al. 2005).  Therefore, 
cyanobacterial toxin exposure assessment is essential to the successful de-
sign and implementation of studies to investigate the risk of cancer associ-
ated with repeated exposure to these toxins. 
Because of the lack of currently identified cyanobacteria toxin–specific 
health effects, we urgently need to develop specific biomarkers of expo-
sure and effect to use in health studies.  Biomarkers of exposure include 
the toxin itself, metabolites of the parent compound, and DNA or protein 
adducts specific to the toxin.  Recently, the use of a simple colorimetric as-
say was proposed to screen human serum samples for the presence of mi-
crocystins (Hilborn et al. 2005).  Work is in progress to identify cylindros-
permopsin metabolites and possible adducts that can be used as human 
biomarkers of exposure (Humpage and Falconer 2005).  Biomarkers of ef-
fect include: biochemical markers such as serum concentrations of liver 
transaminases, and quantification of micronuclei in leukocytes (Falconer et 
al. 1983; Humpage et al. 2000a).  The use of biomarkers will strengthen 
the specificity of association between exposure to cyanobacterial toxins 
and health endpoints.  The carcinogenicity of aflatoxin is now much better 
understood through the ability to measure aflatoxin B1, its metabolites and 
DNA–adducts in urine (Ross et al. 1992; Qian et al. 1994); the epidemiol-
ogy of cyanobacterial toxins awaits similar advances.  Potential future ar-
eas for biomarker development include the use of DNA mutations and ad-
ducts as markers of genotoxicity.  Targeted studies using genomic and 
proteomic techniques may be useful, however are frequently difficult to in-
terpret.  Currently, these approaches are best guided by and aligned with 
the results of traditional toxicologic studies.   
Epidemiologic studies are needed to evaluate the effects of exposures to 
cyanobacteria and their toxins on human and animal health.  Population–
based observational study designs that assess cyanobacteria exposure ret-
rospectively are probably the most cost–effective approaches to investigate 
cyanobacteria bloom–associated health effects at this time.  Of particular 
importance are recent event–triggered investigations.  Both acute and 
chronic health effects may be investigated.  However, assigning exposure 
histories to individuals may be problematic, particularly to those individu-
als or populations with chronic or episodic exposures.  Retrospective stud-
ies may lack the information to examine the temporal relationship between 
exposure and effect, and one design, the case–control study, requires spe-
cific case definitions which are not well defined at present.   
Prospective population–based observational studies have a greater abil-
ity to associate exposure and effect due to improved exposure assessment, 
which is done before health effects occur.  However this approach requires 
large numbers of exposed persons, is expensive, and time consuming.  The 
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dynamic nature of cyanobacteria blooms and toxin production presents 
significant challenges for exposure characterization, study planning and 
implementation.  
An experimental study design can provide a higher degree of the cer-
tainty of associations between exposure and effect.  The principal advan-
tage of a large, randomized, controlled exposure study is that random as-
signment to a study group minimizes the differences between exposure 
groups that may affect the interpretation of the study results.  However, the 
specific details of any proposed randomized exposure trial would need to 
be closely reviewed for its scientific merits and for the protection of hu-
man subjects.  Within human ethical guidelines, an experimental design 
could, in theory, be applied to the study of certain acute, low risk expo-
sures to cyanobacteria.  However, randomized, controlled exposure studies 
are expensive and labor intensive, and therefore are not recommended as a 
research priority at this time.  Resources should instead be directed to the 
implementation of well–designed observational studies to investigate the 
effects of human exposures to ambient concentrations of cyanobacteria and 
their toxins.  
Charge 4: What research is needed to better understand the 
public health effects of exposures to cyanobacteria? 
Near-term Research Priorities 
• Develop specific biomarkers of exposure and effect.  
• Implement retrospective population–based observational studies.  
• Systematically collect descriptions of exposed and ill individuals (cases) 
and case series. 
Long-term Research Priorities 
• Implement prospective population–based observational studies in those 
communities with recurrent exposure events. 
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Charge 5 
What are the determinants of host susceptibility? 
 
Human beings are a diverse lot, varying in age, sex, genetics, nutrition, ex-
posure history and health status.  Accurate prediction of the human health 
risks of cyanobacterial toxins must be based on recognition that each one 
of these variables, either alone or in combination, could affect an individ-
ual’s susceptibility to the effects of these toxins.  However, little informa-
tion is available at this time regarding the importance of these (and other) 
factors in determining host susceptibility.  This lack of knowledge is due 
primarily to the sporadic nature of poisoning episodes in humans and in 
other animals (i.e. wildlife, livestock, domestic animals), and the absence 
of a centralized mechanism for collecting and summarizing data from 
these types of events.  Laboratory studies have focused largely on toxicity 
produced by acute exposures in relatively homogenous laboratory test spe-
cies, such as mice.  Some useful data exists on the effects of cyanobacterial 
toxins in some domestic animals (Falconer 2005).  However, there is far 
less data on the effects of toxins following sublethal acute, episodic or 
chronic exposures.  As a result, attempts to predict the human health risks 
of cyanobacterial toxins are riddled with uncertainty. 
Despite the paucity of data, it seems likely that several factors could in-
fluence the severity of outcome in humans following exposure to cyano-
bacterial toxins.  For example, liver failure would likely be more common 
following exposure to hepatotoxins in people with prior hepatic disease or 
insufficiency, and irritation caused by exposure to air–borne toxins may be 
greater in people with underlying respiratory disease.  
Studies on laboratory animals are potentially more informative in identi-
fying host susceptibility factors.  The most common practice, referred to as 
the mouse bioassay, acutely exposes mice by the i.p. route to samples sus-
pected to contain cyanobacterial toxins (Sullivan 1993).  This approach has 
been widely used to determine the safety of seafood samples, as well as to 
gauge potency during the extraction and purification of toxins from envi-
ronmental samples.  A premium has therefore been placed on standardized 
conditions of testing among samples (Fernandez and Cembella 1995).  As 
a consequence, the potential importance of most susceptibility factors that 
may be prevalent in the human population is unknown.    
Two episodes of human poisonings have focused attention on age as a 
potential risk factor for adverse health effects.  For example, a large scale 
outbreak of toxicoses among renal dialysis patients in Brazil found that 
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mortality was significantly higher among older (47 vs. 35 year old) pa-
tients (Jochimsen et al. 1998).  However, these patients were ill, and ex-
posed to cyanobacterial toxins by the intravenous route; this finding may 
not be applicable to people in general.  Another large–scale poisoning epi-
sode involved exposure to Cylindrospermopsis via drinking water in Aus-
tralia (Hawkins et. al 1985; Falconer 2005).  This outbreak of hepato–
enteritis affected considerably more children that adults.  However, in con-
trast to children, very few adults in the community drank from the local 
water supply.  Therefore, the higher rate of intoxication observed among 
children in the population may have been due to exposure rather than to 
age–related susceptibility.  The role of human genetic susceptibility to ef-
fects associated with cyanobacterial toxins is unknown.   
Some laboratory animal data indicate that age at exposure may influence 
susceptibility to cyanobacterial toxins.  For example, the acute LD50 in rats 
of an extract prepared from Alaskan butter clams containing paralytic 
shellfish poisoning (PSP) toxins increased with age; it is has been surmised 
that the principal toxin in this extract was saxitoxin (WHO 1984).  Com-
pared to newborn rats, adult rats were about 10 times less sensitive follow-
ing oral exposure, and about 2 times less sensitive following i.p. exposure 
to the extract (Watts et al. 1966).  Regardless of age, however, LD50 values 
were considerably lower for the i.p. than the oral route of dosing (Wiberg 
and Stephenson 1960).  On the other hand, in mice receiving a reported i.p. 
LD50 of purified microcystin LR, the time to death decreased substantially 
with age (from 6 to 36 weeks).  A similar age–related decrease in time to 
death was also reported following an oral LD50 exposure of mice to a mi-
crocystin–containing extract (Rao et al. 2005).  Recent studies found no 
developmental or long–term effects in mice following repeated prenatal 
exposure to sublethal doses of microcystin LR, or anatoxin–a (Chernoff et 
al. 2002; Rogers et al. 2005; MacPhail and Jarema 2005).  These latter 
studies highlight the importance of systematic investigations into the ef-
fects of sublethal exposures involving acute, episodic and chronic expo-
sures, in order to make accurate estimations of the health hazards associ-
ated with cyanobacterial toxins. 
5Charge 5: What are the determinants of host susceptibility? 
Near-term Research Priorities 
• Systematically examine and report susceptibility among multiple test 
species of animals exposed to cyanobacterial toxins in toxicology 
studies. 
• Collect and report information about susceptibility during case reports 
and observational studies of humans and animals exposed to 
cyanobacterial toxins. 
• Implement studies of the effects of sublethal acute, episodic and chronic 
exposures in healthy animals and in animal models of susceptibility. 
Charge 6 
What are the research needs after exposure/intoxication has oc-
curred?  
 
Little is known about the potential for human health effects that may per-
sist or develop after intoxication with cyanobacterial toxins, although long 
term effects of microcystin poisoning in sheep have been reported (Carbis 
et al. 1995).  A better understanding of post intoxication effects will de-
pend upon longer–term toxicological studies and upon comprehensive epi-
demiological evidence, including longitudinal studies initiated after recog-
nition of human and animal exposures.  
Timely recognition of exposure events is needed.  In global terms, hu-
man exposures to cyanobacterial toxins in drinking water supplies may oc-
cur sporadically as a consequence of treatment failures, deficiencies in 
drinking water systems operations, or from the addition of copper sulfate 
to reservoirs to terminate blooms of cyanobacteria.  Epidemiological evi-
dence is useful to describe the relationship between cyanobacterial toxin 
exposure and human health outcomes.  However, comprehensive informa-
tion is difficult to collect due to the lack of knowledge of the risk of human 
exposure to cyanobacterial toxins by water quality managers.  When po-
tentially toxic cyanobacterial blooms occur, they may be unrecognized as a 
health threat and public health authorities may not be involved early in the 
process.  Therefore, the majority of outbreaks of human cyanobacterial 
94     E.D. Hilborn et al. 
Chapter 26: Human Health Effects Workgroup Report      595 
toxicoses have been studied retrospectively and complete epidemiological 
and environmental data has rarely been available.  
A similar lack of knowledge may preclude identification of potential 
adverse health effects associated with other potential routes of cyanobacte-
rial toxin exposure such as recreational water activities, consumption of 
contaminated fish, or dietary supplements contaminated by toxic cyano-
bacteria.  Ideally, for health effects research, these risks would be recog-
nized during the period of exposure to toxic cyanobacteria, and measures 
taken to protect human health.  This timely identification of exposure 
would allow better collection of epidemiological evidence and conse-
quently improve the analysis of associated health effects and recovery.  
Although there are no known antidotes to treat poisonings associated 
with cyanobacterial toxins, people and animals may be treated by various 
supportive measures such as intravenous fluid and electrolyte replacement, 
corticosteroid therapy, assisted ventilation, and maintenance of acid–base 
balance.  Methods to reduce absorption such as gastric lavage, activated 
charcoal or cholestyramine may also be used.  
Potentially, if hepatotoxin poisoning is recognized soon after exposure, 
survival may be improved using recent advances in acute liver support 
therapy.  Therapeutic use of the bioartificial liver, the molecular adsorb-
ents recirculating system, portal vein arterialisation and human hepatocyte 
transplantation may supplement the standard treatment for fulminant liver 
failure – liver transplantation (Park and Lee 2005; Hay 2004; Nguyen et al. 
2005; van de Kerkhove et al. 2005; Nardo et al. 2005; Baccarani et al. 
2005; Tissières et al. 2005).  
Maintenance of tissue oxygenation by intermittent positive pressure 
ventilation may benefit victims of neurotoxin poisoning.  Some have in-
vestigated this technique for anatoxin–a poisoning, with mixed results 
(Carmichael et al. 1975; Carmichael et al. 1977; Beasley et al. 1989; Val-
entine et al. 1991).  Artificial ventilation in conjunction with the potassium 
channel blocker 4–aminopyridine has shown promise in reversing experi-
mental saxitoxin poisoning (Chang et al. 1996).  
However, emergency interventions on human and animal victims of 
cyanobacterial toxicosis can only make a limited contribution to the under-
standing of post–intoxication intervention, as typically little is known 
about the total absorbed dose.  There is a need for experimental work de-
signed specifically to investigate the efficacy of various therapeutic ap-
proaches.   
Although a large number of animal poisonings and animal toxicity tests 
have been reported, few have measured the effects of chronic or sub–
chronic exposure (Falconer et al. 1988; Guzman and Solter 1992; Falconer 
et al. 1994; Fawell et al. 1994; Ito et al. 1997; Humpage et al. 2000b; Fal-
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coner and Humpage 2001; Humpage and Falconer 2003).  Therefore, the 
long–term risk associated with chronic, low–level exposure is less well 
understood.  However, this type of exposure scenario may be the most 
common among human populations.  The relative lack of animal data 
makes epidemiological studies difficult due to the lack of case definitions 
and biologic methods to confirm evidence of chronic or subchronic expo-
sure to low levels of cyanobacterial toxins (Kuiper–Goodman et al. 1999).
  
There is a great disparity of information among cyanobacterial toxins. 
Microcystins are the group of toxins most frequently studied, and there is 
more information to support the understanding of the intoxication and de-
toxification process.  However, even in the case of microcystins, research 
into long–term exposures is needed to investigate reproductive toxicity, 
teratogenicity and carcinogenicity effects in mammals.  For other cyano-
bacterial toxins, such as cylindrospermopsin and the neurotoxins, anatox-
ins and saxitoxins, there are large knowledge gaps related to chronic toxic-
ity and to the intoxication and detoxification process.  
Charge 6: What are the research needs after exposure/ 
intoxication has occurred? 
Near Term Research Priorities 
• Initiate regular monitoring of water bodies at risk for toxic cyano-
bacteria blooms to enable remediation and timely health effects studies. 
• Implement toxicologic studies that encompass multiple health endpoints 
at frequent time intervals to examine the relationship between initial 
intoxication, health effects and recovery at multiple life stages. 
• Conduct studies to investigate the effectiveness of therapeutic ap-
proaches. 
• Monitor food and supplements at risk for contamination with cyano-
bacterial toxins to enable public health intervention and timely health 
effects studies. 
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Charge 7 
Where are we in the development of predictive models? 
 
Predicting human health outcomes associated with cyanobacterial toxins 
requires linking exposure estimates with dose–response models.  Estimates 
of toxin occurrence may be potentially derived from the models of bloom 
dynamics, toxin production, and the fate and transport of the toxins. 
Mechanistic models have been developed that can simulate a variety of 
bloom characteristics and they have been useful in determining the signifi-
cance of a variety of environmental variables that influence bloom dynam-
ics (Bonnet and Poulin 2002; Thébault and Rabouille 2003; Håkanson et 
al. 2003; Robson and Hamilton 2004; Arhonditsis and Brett 2005; Prokop-
kin et al. 2006) but their predictive capacity remains limited.  In contrast, 
inductive models, such as those employing artificial neural networks, ap-
pear to have the capacity to predict significant aspects of bloom dynamics 
(Recknagel et al. 1997; Maier et al. 1998; Jeong et al. 2003). 
A key step in using predictive models of bloom dynamics to predict ex-
posures will be consideration of toxin fate and transport within aquatic 
ecosystems.  This will help to determine the relative importance of differ-
ent routes of human exposure to cyanobacterial toxins.  For example, there 
is a potential for oral, inhalational and dermal exposures during recrea-
tional water use.  Microcosm studies may provide an efficient means to 
develop and evaluate the models that integrate bloom dynamics, toxin pro-
duction, fate and transport to estimate such multi–route exposures.  Reli-
able models predicting exposure via drinking water may be more difficult 
to link to bloom dynamics given the uncertainties regarding the fate of tox-
ins in water processing and the potential for by–products resulting from the 
interaction of disinfection agents with cyanobacterial toxins. 
Mechanistic models of human health effects based on stepwise links 
from exposure to effect require toxicokinetic and toxicodynamic infor-
mation that is largely unavailable for the majority of cyanobacterial toxins. 
Furthermore, dose–response information is only currently available for a 
small number of toxins for limited types of effects, suitable for use in more 
basic modeling efforts.  Alternatively, more 'intelligent' inductive models 
may be used to predict human health outcomes from mixtures of cyano-
bacterial toxins based on data derived from experimental studies that em-
ploy characterized bloom extracts rather than pure toxin.  While such ex-
tracts more accurately represent individual real–world blooms, their 
complex and unique characteristics may limit the inferences that can be 
made until large numbers of blooms are characterized and their effects as-
sessed. 
The development of predictive models may also benefit from a more ex-
tensive characterization of the influence of temporal aspects of exposure 
on various types of health outcomes.  Different health outcomes are likely 
to predominate as a result of acute, subchronic, chronic and episodic expo-
sures.  Only minimal data are currently available that are suitable for dis-
criminating the impact of these temporal aspects of exposure on the variety 
of potential human health outcomes.  Predictive models are needed that 
may be used by risk managers during decisions related to the costs and 
benefits of surface water use and exposure. 
To the extent that future experimental studies implicate a wider variety 
of health outcomes as being influenced by cyanobacterial toxin exposure, 
models will need to be developed to address more comprehensive predic-
tions that include a variety of health outcomes in the human population. 
Evaluation of such predictions will require corresponding biomarkers of 
effect suitable for use in human populations to evaluate the validity of 
model predictions. 
While the primary linkage between bloom occurrence and human health 
effects is presumed to be exposure to cyanobacterial toxins, the effects of 
cyanobacterial blooms on ecosystem services may also influence human 
health.  While several international efforts are modeling the impact of 
cyanobacterial blooms on ecosystems, assessing the impact of ecosystem 
services on human health is emerging as an important area of research.  At 
this time it is difficult to assess the significance of ecosystem services for 
modeling the effect of cyanobacteria blooms on human health. 
Charge 7: Where are we in the development of predictive 
models? 
Near-term Research Priorities 
• Implement toxicology studies to determine dose–response relationships 
using oral, inhalational and dermal exposure routes.  
• Implement studies of cyanobacterial toxin fate and transport in 
environmental media. 
• Characterize the toxicokinetics/toxicodynamics of parent toxin and 
metabolites. 
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Long-term Research Priorities 
• Develop linkages between predictive models of bloom dynamics to 
dose–response models of human health and ecologic effects outcomes. 
• Investigate how cyanobacterial blooms reduce ecosystem services, and 
the resulting effects on human and animal health. 
Conclusion 
In summary, we have identified multiple health effects research needs as-
sociated with exposure to cyanobacteria and cyanobacterial toxins.   
• Affordable toxin standards are needed.  However, in the short term, 
research may be conducted with characterized clonal cyanobacteria 
cultures that can be shared among laboratories. 
• Studies of the health effects of chronic, episodic, and low–dose 
exposures by environmentally—relevant routes are needed.  Carcin-
ogenicity, neurodevelopmental, neurotoxicology, and immunotoxic-
ology studies are of immediate importance.  
• Experimental studies of laboratory animals and observational studies of 
populations exposed to mixtures of cyanobacterial toxins are needed.  A 
goal is to develop risk assessments of populations exposed to natural 
blooms and mixtures of cyanobacterial toxins. 
• The public health consequences of exposure to cyanobacteria and 
cyanobacterial toxins are poorly characterized.  Biomarkers of exposure 
and effect are needed to use in human studies.  Case reports and 
observational epidemiologic studies are needed.  
• Host susceptibility is poorly defined and should be systematically 
examined among individuals involved in outbreaks of toxicoses, and 
during experimental and observational studies. 
• Timely and accurate exposure assessment is critical to detecting and 
understanding cyanobacterial toxin—associated health effects.  System-
atic toxin occurrence monitoring is needed in water and food at risk for 
contamination with potentially toxic cyanobacteria. 
• Critical data gaps remain before predictive modeling of cyanobacteria–
associated health effects in populations is possible.  Information about 
the environmental fate and transport of toxins, the effects of cyano-
bacteria blooms on ecosystem services and population dynamics, the 
toxicokinetics/toxicodynamics of parent compounds and metabolites, 
and dose–response data are needed. 
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